BACKGROUND: We tested the hypothesis that trisomy risk is increased for women with fewer oocytes (older ovarian age) than other women of the same chronological age. METHODS: Our study compared three indicators of ovarian ageÐnumber of antral follicles, level of dimeric inhibin B, level of FSHÐamong women who had trisomic pregnancy losses (n = 54) with those among women who had other losses (24 with other chromosomally abnormal loses, 21 with chromosomally normal losses) or who had chromosomally normal births (n = 65). RESULTS: Ovarian age indicators did not differ between women with trisomic spontaneous abortions and the three comparison groups. Compared with live birth controls, adjusting for chronological age, we estimate that, on average, among trisomy cases the geometric means of 1 + follicle count, inhibin B and FSH are about 7.5% higher, 16.6% higher and 5.5% lower, respectively, with all 95% con®dence intervals including zero. The sample size was suf®cient to detect moderate differences (0.52 standard errors of regression) between trisomy cases and live birth controls. CONCLUSIONS: Although our data do not support our hypothesis, they leave open the possibility that changes in follicular development unrelated to the size of the oocyte pool in¯uence abnormal chromosome segregation.
Introduction
This study sought to elucidate the well-established association of maternal age with autosomal trisomy, the most common chromosomal abnormality in human conceptions. At least 3% of clinically recognized pregnancies are trisomies; >90% end in spontaneous abortion (Kline et al., 1989) . As women age, trisomy increases in frequency both for the minority of trisomies compatible with survival [primarily trisomies 13, 18 and 21 (Down's syndrome)] and for the majority of trisomies that abort spontaneously (Hassold and Chiu, 1985; Risch et al., 1986) . The extra chromosome is usually of maternal origin, almost always due to error during maternal meiosis I (Lamb et al., 1996; Hassold and Hunt, 2001) .
It seems reasonable to infer that trisomy results from physiological processes that are intimately tied to chronological age. One candidate process is the age-related decline in the size of the ovarian oocyte pool (oocyte atresia). We hypothesized that the association between chronological age and trisomy re¯ects a causal connection between the size of the oocyte pool (ovarian age) and trisomy, with risk higher in women with fewer oocytes (Warburton, 1989; Kline and Levin, 1992) . Studies of autopsy and surgical specimens show that the germ cell population, which is largest during fetal development (~7Q10 6 ), decreases approximately exponentially with chronological age (Block, 1952; Baker, 1963; Thomford et al., 1987; Faddy et al., 1992; Leidy et al., 1998) . Despite the overall decline in oocyte count with age, counts vary among women of any given chronological age. Variability may re¯ect differences either in the number of oocytes laid down or in the rate of atresia, each potentially in¯uenced by endogenous or exogenous factors.
Several observations support the idea that the size of the oocyte pool may in¯uence trisomy risk. (i) The rate of aneuploidy is higher in middle-aged mice in which one ovary was removed than in sham-operated mice (although the majority of anomalies are monosomy, not trisomy) (Brook et al., 1984) . In women, observations relating oophorectomy to trisomy are inconsistent (Freeman et al., 2000; Warburton and Kline, 2001) ; inferences from both studies are limited by the small number of women with oophorectomies. (ii) Age at menopause may occur earlier in women who had trisomic spontaneous abortions than in women who had chromosomally normal pregnancies (Kline et al., 2000) . (iii) One study (van Montfrans et al., 1999) suggests that elevated levels of FSHÐ which might re¯ect either diminution of the underlying oocyte pool or impaired function of the developing cohortÐare more common in women after a Down's syndrome birth than in controls. Another study (Nasseri et al., 1999) , drawing mainly on a sample of women pregnant by assisted reproductive technology, suggests that raised levels of either FSH or estradiol are more common in women with chromosomally abnormal (80% of which were trisomic) versus chromosomally normal spontaneous abortions; the authors do not report associations for the two hormones separately.
An association might arise through various routes. The biological ageing hypothesis focuses on proximity to menopause, postulating that a factor associated with depletion of the oocyte pool, such as hormonal imbalance, in¯uences the likelihood of abnormal chromosomal segregation at ovulation (Brook et al., 1984) . The limited oocyte pool hypothesis focuses on the small cohort of follicles that develop during each menstrual cycle (Warburton, 1989) . Like the total pool, the number of developing follicles diminishes with chronological age (Block, 1952; Gougeon et al., 1994; Reuss et al., 1996; Scheffer et al., 1999) . The hypothesis proposes that the chance that an oocyte is available at the optimal stage of maturation decreases as the number of developing follicles decreases; immature or post-mature oocytes are hypothesized to be more liable to abnormal chromosome segregation.
Our study compares indicators of ovarian age among women who had trisomic losses with those among women who had other losses (chromosomally normal or non-trisomic chromosomally abnormal) or with chromosomally normal births. The three primary indicators of advanced ovarian age are low number of antral follicles, low level of dimeric inhibin B, and high level of FSH. The number of antral follicles provides an indirect measure of the size of the underlying oocyte pool. Inhibin B, a product of the cohort of developing follicles (Burger, 2000) , re¯ects their quantity and quality. FSH, a gonadotrophin under negative feedback of two ovarian hormones, estradiol and inhibin (Burger, 1994 (Burger, , 2000 , re¯ects the competence of the developing pool; FSH may also provide an indirect measure of the underlying oocyte pool (Goldenberg et al., 1973; Klein et al., 2002) . We measured estradiol because some reports suggest that in older regularly cycling women the dominant follicle emerges early, with a consequent early rise in estradiol level (Klein et al., 1996a (Klein et al., , 2000 .
Materials and methods
The protocol From September 14, 1998, to April 2, 2001, we identi®ed women aged b18 years with singleton prefetal losses (developmental age <9 weeks) whose products of conception were submitted to the Pathology Department of a hospital in New York State. We asked for permission to karyotype the abortus. If a woman's loss was successfully karyotyped, we asked her to complete a short telephone interview to determine her eligibility. Eligible women who consented to the protocol: (i) completed a more extensive telephone interview regarding demographic characteristics, obstetric and medical histories, and common exposures; (ii) recorded their menstrual periods; (iii) made two visits to the study hospital during the ®rst week of their second or later menstrual cycle, the ®rst on day 1±4 for a blood draw and the second on day 5±7 for transvaginal sonography and a brief interview regarding recent exposures; (iv) reported the date of the menses following the sonography visit. Women with trisomic losses constitute the case group. Women with chromosomally normal losses or non-trisomic chromosomally abnormal losses constitute two of the comparison groups; women with chromosomally normal births constitute the third. For women who completed the protocol and whose abortus was karyotyped as normal female, we attempted to con®rm the karyotype with DNA analysis of ®ve highly polymorphic markers in maternal blood and fetal tissue.
For each woman with a trisomic loss (case) who completed the study, we selected an age-matched control with a chromosomally and anatomically normal live birth b1800 g, no pregnancy loss since the index pregnancy and no known trisomic pregnancy. They were selected from the hospital delivery log of women who delivered during the 7±13 months preceding the date of selection. Live birth controls were matched to trisomy cases for projected age (T 6 months) at the sonography visit. If a selected control was ineligible for the study or refused to participate, we replaced her. The study was approved by our Institutional Review Boards and all participants gave informed consent. Fieldwork ended in November 2001.
The protocol for live birth controls was identical to the protocol for women with prefetal losses. The interviewer knew the outcome of the index pregnancy, but she did not know the karyotype of the loss (except in about two instances when the subject revealed it). Follicles were counted and hormones assayed without knowledge of any subject characteristics, including the outcome of the index pregnancy.
To obtain valid ovarian age measures, we required: no pituitary disorder or hormonal disorder related to ovarian function, no oophorectomy, no hormonal medication, no pregnancy at the time of ultrasound, no breastfeeding or breastfeeding no more than once per day during the menstrual cycle preceding the study assessments. We required that any diagnosis be current, the report of the diagnostic work-up informative and the clinical symptoms and treatment consistent with the diagnosis. The study reproductive endocrinologist (A.C.K.) reviewed the interview data to determine whether or not a potential participant currently had a condition associated with altered hormone levels.
Participants

Spontaneous abortions
From 435 prefetal losses identi®ed, we set up 269 specimens in culture and karyotyped 244 (Table I ). The principal reasons for not setting up a tissue culture were patient refusal of the karyotype offer (17%) and insuf®cient fetal tissue (15%). Among the 244 women with karyotyped losses, 127 (52%) completed the protocol. The principal reasons for not completing the protocol were: refusal (23%) and ineligibility (25%), primarily due to use of hormonal contraceptives (10%) or pregnancy soon after the index loss (7%). Six women (2%) were excluded because of hormonal conditions and another six were excluded due to use of fertility drugs, although only two had experienced conception delay >1 year prior to the study pregnancy.
Women who completed the protocol were on average older than women who did not. The age difference arose chie¯y because younger women were more likely to begin hormonal contraception immediately after their loss. Among the 205 women who completed the eligibility interview, adjusting for age, the odds of completing the protocol did not differ with education, parity or number of prior induced abortions; completion rates were signi®cantly higher in women with one or more prior spontaneous abortions than in women with no prior losses (74 versus 56%).
Analyses exclude 24 women for whom we consider the karyotype of the abortus uncertain: the abortus was karyotyped as a chromosomally normal female, but we could not con®rm the validity of the diagnosis by comparison of maternal and fetal DNA (Table I , footnote i). Analyses also exclude repeat study pregnancies to four women who had a trisomic loss on either their ®rst or second pregnancy (Table I , footnote h). The analytical sample thus includes 99 women: 54 with trisomic or hypertriploid losses (cases), 24 with other chromosomally abnormal losses and 21 with chromosomally normal losses (17 male, four female).
Live birth controls
During the ®rst 6 months of the study, we selected live birth controls before we knew the eligibility and consent status of the matched case; as a result, four controls completed the protocol even though their matched cases did not. For most of the study, controls were selected after the case had agreed to the protocol. We selected second or later controls when: (i) a control declined the study or was ineligible or (ii) >2 1 2 months elapsed without our having spoken to the ®rst control or (iii) we were unable to scan both ovaries of the ®rst control. During the ®nal 3 months of the study, to speed completion of the ®eldwork, we selected additional controls before 2 1 2 months had passed. In total, we selected 219 controls; 65 (30%) completed the protocol. The principal reasons for not completing the protocol were refusal (31%) and ineligibility (37%), primarily due to use of hormonal contraceptives (17%) or breastfeeding (10%). Two women (1%) were excluded because of hormonal conditions.
Women who completed the protocol were on average older, though not signi®cantly so, than women who did not. Among the 144 women who completed the eligibility interview, the odds of completing the protocol did not differ with educational attainment, parity, number of prior induced abortions or number of prior spontaneous abortions.
The analytical sample comprises 65 women who completed the protocol. Sixty of the 65 were matched at the time of selection to one of the 54 trisomy cases. An additional ®ve live birth controls were matched post hoc to trisomy cases of the same age.
Characteristics of women with losses, classi®ed by karyotype, and live births Maternal age was similar for women with trisomic losses and live birth controls; women with non-trisomic chromosomally abnormal losses and women with chromosomally normal losses were younger (Table II) . Adjusting for age, none of the demographic or exposure variables (education, ethnicity, obstetric history or smoking) were related to the outcome of the index pregnancy. The majority of women completed the blood and sonography protocols after the second or third menstrual period following the index loss or, for live birth controls, the introductory letter. Protocol menstrual period, day of blood sampling and day of sonography were unrelated to the outcome of the index pregnancy.
Indicators of ovarian age
Antral follicles
We used four transducers over the course of the study: the ®rst two, Acuson EXP 128, operated at a frequency of 7 MHz; the second two, Acuson Sequoia (8±10 MHz) were usually used at 10 MHz. The sonography technician scanned each ovary in transverse and longitudinal views at a subjectively constant velocity, repeating scans, as needed, until she obtained an optimal scan. When one ovary was inaccessible at the ®rst scan (n = 11)Ðeven though, based on history and transabdominal scans, each woman was known to have two ovariesÐwe attempted a second scan during the woman's next cycle. Four women made a second visit; for two we were able to scan both ovaries. The sample thus included 155 women with both ovaries scanned and nine with a single ovary scanned.
We videotaped the sonography scan. The sonographer (M.L.R.) identi®ed the optimal scan, converted it to a digitized format and exported it to Matrox Inspector software for follicle counting and measurement. The scans were counted in four batches, each batch a Includes 14 women (two with prefetal losses, 12 with live births) who provided information on their eligibility status but declined the eligibility interview. b Sixty-one women were taking oral contraceptives; two live birth controls had intrauterine devices that included a hormonal component. Two live birth controls were also breastfeeding. c One live birth control was also breastfeeding. d Five women (four with prefetal losses, one live birth control) had been diagnosed with polycystic ovary disease, two women (one with a prefetal loss, one live birth control) with hyperprolactaemia, and one woman with a prefetal loss had been diagnosed with anovulation. e One woman with a prefetal loss was taking oral contraceptives to regulate her periods (oligomenorrhoea, possible polycystic ovary disease). One live birth control was taking progesterone`for a possible cyst'. f One woman with a prefetal loss did not complete the protocol within 8 months of her spontaneous abortion. One live birth control had had a previous trisomic conception. g Includes single and double autosomal trisomies, hypertriploids and hypertetraploids. h One tetraploid, one monosomy X, one trisomy 16, one normal male (the woman had a subsequent trisomy but was ineligible for the study at that entrance because she had already become pregnant again). i Chromosomally normal female karyotypes may re¯ect the true karyotype of the abortus or inadvertent culturing of maternal cells. We therefore reanalysed specimens karyotyped 46,XX, where possible, by comparing ®ve highly polymorphic markers in maternal blood and fetal tissue. Of the 28 women who completed the study whose abortuses had been karyotyped 46,XX, we con®rmed four by DNA analysis. Analyses exclude the remaining 24 women for whom DNA analysis was either not possible because of inadequate specimens (n = 21) or indicated inadvertent karyotyping of maternal cells (n = 3). j Eight monosomy X, ®ve triploid, ®ve tetraploid, one 47,XYY, ®ve rearrangements.
including trisomies, other losses and live births. Within each batch, we randomly allocated scans of left and right ovaries and randomly ordered scans. The randomization procedure was unknown to the sonographer. We adjusted for batch number in our initial analyses, but not in the ®nal analyses (see below). Each sonolucency interpreted as a follicle was followed through the scan to identify its maximum size; its largest diameter was measured in the vertical plane using the centimetre scale generated by the ultrasound machine. To assess the reliability of the counting procedure, we counted again the follicles in 40 ovaries (from seven women with trisomic losses, six with other losses, seven with births). The intraclass correlation coef®cient (ICC) was 0.92. We evaluated reliability early in the study (after 12 scans were completed) and at the end. The ICC of the ®rst 12 scans (0.83) was excellent (Fleiss, 1986) ; the ICC of the two later reliability samples (0.97 for the second 12 scans, 0.92 for the ®nal 16 scans) were even better. Analyses use the second count for the 20 women whose scans were counted twice. e For nine women, the second ovary was not accessible at the time of sonography. We imputed the number of follicles in the ovary that was not scanned based on a regression equation that included age and the number of follicles in the scanned ovary. Among the 155 women with both ovaries scanned, counts ranged from 2 to 70 (median 15, mean 18.5, SD 13.0). The mean difference between counts in the left and right ovaries was 0.34 (SD = 5.52, range ±15 to 28). The correlation between them was 0.70 (P < 0.0001). For the nine women with one ovary scanned, we imputed the total number of follicles in the ovary not scanned from regression equations that included age and the number of follicles in the contralateral ovary. Results were unchanged when we excluded women with imputed counts from the analysis.
Serum hormone levels
Blood samples were processed in a refrigerated centrifuge and, after separation, sera were frozen at ±25°C at the study hospital; they were shipped to New York City and stored at ±20°C. Dimeric inhibin B was measured by radioimmunoassay (Oxford Bio-Innovation Ltd); FSH and estradiol were measured by solid-phase chemiluminescent enzyme immunoassays (Immulite; Diagnostic Products Co.). For inhibin B, sensitivity was 20 pg/ml; intra-and inter-assay coef®cients of variation (CV) were 5.1% and 6.2% respectively. For FSH, sensitivity (the minimum detection limit) was 0.1 mIU/ml; intra-and inter-assay CV were 9.3% and 10.5% respectively. For estradiol, sensitivity was 20 pg/ml; intra-and inter-assay CV were 1.9% and 5% respectively. Table III shows summary statistics for antral follicle count and hormone levels and their correlations with chronological age. Correlations with count, inhibin B and FSH are in the expected directions. For estradiol, the modest positive correlation is compatible with observations that levels may be elevated during the menopausal transition (Klein et al., 1996b (Klein et al., , 2000 .
The statistical analysis
The data The data consist of 54 strata, one for each trisomy case. Each stratum includes (i) the originally selected live birth control(s); 29 strata also include (ii) women with chromosomally normal or non-trisomic chromosomally abnormal losses matched for chronological age to the stratum's trisomy case; four strata also include (iii) one or more of the ®ve live birth controls whose cases are not in the analytic sample. Women in the two pregnancy loss comparison groups, as well as the ®ve live birth controls strati®ed post hoc, were matched to the trisomy case to whom they were closest in maternal age. The average withinstratum age differences between the trisomy cases and comparison groups were: for non-trisomy chromosomally abnormal losses, 0.07 years (95% CI ±0.06, 0.20); for chromosomally normal losses, ±0.14 years (95% CI ±0.27, ±0.002); and for live births, ±0.05 years (95% CI ±0.14, 0.03). In only one instance was the age difference between a trisomy case and any of her matched controls >1 year; 94% of the differences were`6 months.
Primary analysis
We ®rst examined associations with each of the ovarian age indicators separately. We used strati®ed multiple linear regression models to test the null hypothesis that, at any maternal age, there is no difference between trisomy cases and any of the three comparison groups in antral follicle count or hormone measures. We estimated the magnitude of differences between trisomy cases and each comparison group and set 95% CI around these. We used a logarithmic transformation for count of antral follicles, ln(1 + count), and each hormone to meet the normal error assumption of least squares regression. Thus, differences correspond approximately to percentage changes in the hormone measures and to percentage changes in 1 + antral follicle count. We checked the results in a complementary analysis using polytomous conditional (matched sample) logistic regression (Breslow and Day, 1980; Levin, 1987 Levin, , 1990 ; for these analyses, we classi®ed each of the ovarian age measures in three categoriesÐvalues in the lowest 20th percentile, values in the upper 20th percentile and, as the reference group, values between the 20th and 80th percentiles (not reported).
Secondary analyses
We explored whether the strength of associations between trisomy and ovarian age measures varies with chronological age or with trisomy type (trisomy 16, other non-acrocentric trisomies, acrocentric trisomies). To address the possibility that associations with trisomy might be attenuated by the presence of women with prior unkaryotyped trisomies (expected to be~3.8%) among controls, we repeated the primary analyses using only the largest comparison group: live birth controls.
We also estimated associations with two indicators of`older ovarian age' that combined our primary measures. The ®rst combination, a priori, de®ned`older ovarian age' as: follicle count`6 (the lower 12th percentile in our data) or inhibin B`20 pg/ml (the sensitivity level of the assay) or FSH b10 mIU/ml (a level, for the Immulite assay, many clinicians use to indicate poor ovarian reserve). For the second indicator, we summed the z-scores for our three primary measures (count, inhibin B, FSH), reversing the sign for count and inhibin so that higher positive z-scores indicated older ovarian age. We de®ned`older ovarian age' as summed z-scores in the upper 14th percentile, corresponding to one or more SD from the mean of the summed z-score. We used conditional maximum likelihood logistic regression to estimate the odds ratios and 95% con®dence intervals relating trisomy to each indicator. As in the analogous matched-pairs analysis, the odds ratio is based only on conditionally informative strata in which the case and control are discordant. We report the results from analyses comparing trisomy cases with live birth controls because the two pregnancy loss comparison groups were too small to be informative. Among the 119 women with trisomic losses or live births, 28 (24%) were classi®ed as having older ovarian age by the ®rst de®nition and 17 (14%) by the second; 15 (13%) were so classi®ed by both de®nitions.
Statistical adjustment
All but one set of analyses±those which test whether associations vary with chronological age±control for age stratum. Analyses of hormones adjust for day of blood draw because inhibin levels were lower on day 1 than days 2±4; a similar trend, of lesser magnitude, was present for FSH. In our initial analyses of follicle count, we adjusted for counting batch; however, because adjustment for batch changed the regression coef®cients very little (i.e. 20±46% of a standard error), we did not adjust for batch in the ®nal models. For each of the four outcomes, we checked the stability of our point estimates against a model that included the maternal demographic and obstetric characteristics, body mass index and smoking and, for follicle count, a model that included batch, transducer and day of sonography. Changes in the point estimates were small. Results were unchanged when analyses were limited to the 49 strata (149 women) in which the ages of all comparison group women were within 6 months of their age-matched trisomy case.
Results
None of the three primary indicators of ovarian age differed between trisomy cases and the three comparison groups (Table IV) . Compared with live birth controls, adjusting for Trisomic pregnancy and the oocyte pool chronological age, we estimate that, on average, among trisomy cases the geometric mean of (1 + follicle count) is about 7.5% higher, of inhibin B is 16.6% higher and of FSH is 5.5% lower, with all 95% con®dence intervals (CI) including zero. These point estimates correspond, for example, to the prediction that at the median values for the sample (i.e. number of antral follicles = 15, inhibin B = 79.5 pg/ml, FSH = 4.4 mIU/ ml; Table III), trisomy cases have follicle counts that are 1.2 higher, inhibin B levels 14.3 pg/ml higher and FSH levels 0.2 mIU/ml lower than live birth controls. For follicle count, similar results obtained when the analysis was limited to (i) the number of medium-sized follicles, de®ned as 3±11.99 mm (to rule out the possibility that small follicles, which might be counted less accurately, had obscured results) or (ii) the 155 women with both ovaries scanned (i.e., excluding women with imputed follicle counts). For inhibin B and FSH, similar results obtained when the analysis was limited to the 44 age-matched strata (137 women) in which all stratum members had blood samples drawn on days 2±4.
Level of estradiol, a secondary indicator, did not differ between trisomy cases and live birth controls (b = ±0.097) or other chromosomally abnormal losses (b = 0.105). Levels were signi®cantly lower in trisomy cases compared with women with chromosomally normal losses (b = ±0.271). At the median estradiol value of 35 pg/ml, our point estimate suggests that levels in trisomy cases are 8.3 pg/ml lower than in women with chromosomally normal losses. The difference between trisomy cases and chromosomally normal losses persisted when analyses were limited to women who had blood samples drawn on days 2±4.
To explore the possibility that associations varied with maternal age, we adjusted for age as a continuous variable (rather than a strati®cation variable) and tested whether differences between trisomy cases and each of the three comparison groups varied with age. We checked the validity of the results from the regression analysis by smoothing the data with locally weighted regressions (Cleveland, 1979) for each pregnancy outcome group separately (Figure 1 ). For follicle count and inhibin B, the pattern of change with age was similar for trisomy cases and the three comparison groups. For FSH, the regression analysis indicated a steeper increase with age among trisomy cases than among live birth controls [b for trisomy±live birth difference in ln(FSH) Q age = 0.035, SE = 0.014, P = 0.015], but no difference between trisomy cases and either of the pregnancy loss comparison groups [b's for the difference in ln(FSH) Q age were ±0.006 in comparison with non-trisomic chromosomally abnormal losses and ±0.005 in comparison with chromosomally normal losses]. FSH levels tended to be higher among trisomy cases than among live birth controls after the late 30s; the two pregnancy loss comparison groups exhibited patterns similar to those of the trisomy case group. For estradiol, the pattern of change with age did not differ between trisomy cases and any comparison group.
Inhibin B levels were signi®cantly higher among women with trisomy 16 losses compared with live birth controls; this ®nding, coupled with (statistically non-signi®cant) increased follicle count and decreased FSH level, suggests younger ovarian age among women with trisomy 16 losses (Table V) . Other non-acrocentric trisomies and acrocentric trisomies did not differ from live birth controls in any ovarian age measure, nor did the patterns of association with the three primary measures suggest that ovarian age was either older or younger. The sample was too small and the correlation between trisomy type and age too close to explore whether or not associations with trisomy type varied with maternal age. The proportions of women aged <35 years were 83% among the 18 women with trisomy 16 losses, 27% among the 15 with other nonacrocentric trisomy losses and 38% among the 21 with acrocentric trisomy losses.
When live birth controls with prior spontaneous abortions were excluded from the analysis, follicle count, inhibin B and FSH did not differ between trisomy cases and live birth controls (Table V) . Estradiol levels were signi®cantly lower in trisomy cases (b = ±0.243). At the median estradiol value of 35 pg/ml, our point estimate suggests that levels in trisomy cases are 7.6 pg/ml lower than those in live birth controls.
With respect to combined indicators of ovarian age, among the 54 trisomy cases, 27.8% met our a priori de®nition of older (We used a smoothing fraction of 1/3. We do not show locally weighted smoothing for ages >43 years because the extrapolations were based on a small number of women.) Table V . Adjusted mean differences a (95% con®dence intervals) in antral follicle count, inhibin B, FSH and estradiol among (i) women with trisomic losses, classi®ed by trisomy type, and women with live births and (ii) women with trisomic losses and women with live births and no prior spontaneous abortions Analysis n Adjusted differences in ln(geometric means) between trisomy cases and live births (95% CI) a All analyses adjust for the age-matched trisomy-live birth strata. Analyses of ln(hormone level) adjust for day of blood sampling (day 1 versus days 2±4). b Obtained from a single strati®ed regression analysis in which each trisomy group was compared with live birth controls. c Includes one hypertriploid 70, XXY, +16. d Includes trisomy 2 (n = 3), trisomy 4 (n = 2), trisomy 8 (n = 4), trisomy 9 (n = 1), trisomy 10 (n = 2), trisomy 20 (n = 2), and hypertriploid (70, XXY, +6/71, XXY +6, +20). e Includes trisomy 13 (n = 4), trisomy 15 (n = 5), trisomy 21 (n = 5, including one double trisomy), trisomy 22 (n = 7). f Twenty-one of the 65 live birth controls had prior spontaneous abortions. Their exclusion rendered 15 trisomy-live birth strata incomplete. The analysis draws on 39 age-matched strata.
ovarian age (i.e. follicle count`6 or inhibin B`20 pg/ml or FSH b10 mIU/ml) compared with 20.0% of the 65 live birth controls (adjusted matched-strata odds ratio = 1.4, 95% CI 0.6, 3.4). For the summed z-score indicator of ovarian age, 11.1% of trisomy cases and 16.9% of live birth controls had measures in the 14th percentile or greater (adjusted matched-strata odds ratio = 0.6, 95% CI 0.2, 1.7). Post hoc analyses of the three components of the a priori measure showed: no association with follicle count`6 (stratum-adjusted odds ratio = 1.0, 95% CI 0.3, 2.9); a positive association with inhibin B`20 pg/ml (stratum-adjusted odds ratio = 1.6, 95% CI 0.6, 4.7); a positive association with FSH b10 mIU/ml (stratum-adjusted odds ratio = 2.8, 95% CI 0.5, 14.6).
Discussion
Our hypothesisÐthat trisomy risk is increased for women with fewer oocytes than other women of the same chronological ageÐled us to predict that women with trisomic pregnancies have fewer antral follicles, lower inhibin B levels and higher FSH levels than expected given their chronological age. Our data do not support the hypothesis. Ovarian age indicators were similar for women with trisomic spontaneous abortions and for women of the same age whose pregnancies ended in non-trisomic chromosomally abnormal loss, chromosomally normal loss or live birth. Results were unaltered by statistical adjustment for several maternal characteristics and exposures or for technical variables (e.g. ultrasound transducer), or when we excluded from the live birth group women with prior spontaneous abortions (which might include undetected trisomies). The sample size was suf®cient (power = 0.80, a = 0.05, two-tailed) to detect differences between trisomy cases and live birth controls (the largest comparison group) equivalent to 0.52 standard errors of regression. At the median value of each indicator (15 antral follicles, inhibin B 79.5 pg/ml, FSH 4.4 mIU/ml), detectable effect sizes correspond to 4.1 fewer follicles, a 22.3 pg/ml decrease in inhibin B and a 1.1 mIU/ml increase in FSH. Our 95% CIs suggest that a decrease in antral follicle count of >13.2%, a decrease in inhibin B of >6.5% and an increase in FSH of >10.4%Ðall small effectsÐare unlikely.
Two a priori de®nitions of ovarian age, which combined data on follicle count, inhibin B and FSH, were unrelated to trisomic loss. Post hoc analyses showed that follicle count`6 (the lowest 12th percentile in our data) was unrelated to trisomy. Inhibin B level`20 pg/ml and FSH level b10 mIU/ ml were positively, but not signi®cantly, associated with trisomy.
Estradiol levels were similar for trisomy cases and live birth controls. A single measure of estradiol on days 1±4, however, may not tap the phenomenon of interest, namely, the earlier emergence of the dominant follicle associated with greater chronological age (Klein et al., 1996a (Klein et al., , 2000 . (The signi®-cantly higher level of estradiol in women with chromosomally normal losses compared to women with trisomic losses may result from chance or may prove informative about the aetiology of chromosomally normal loss.) Fifty-two per cent of women with karyotyped losses and 30% of potential live birth controls completed the study. Nevertheless, we think that our sample fairly represents the ovarian age of the population from which it was drawn. The principal reason for declining the study (22% of women with losses, 31% of women with births) was inconvenience: it is implausible that the ovarian age of women too busy to enroll differed systematically from the ovarian age of women who participated. Among women ineligible for the study (25% of women with losses, 37% of women with births), the principal reasons were hormonal contraceptive use, pregnancy or, for women with births, breastfeeding. Exclusion for pregnancy may have selectively removed more fertile (younger ovarian age) women from the sample. About the same proportion of women with losses (18/61) and with births (12/57 after excluding controls ineligible due to breastfeeding) became pregnant; thus, if pregnancy is a marker of young ovarian age, both the loss and birth samples overestimate ovarian age. Exclusion of women who used hormonal contraceptives would lead to bias only if contraceptive method relates to ovarian age (unknown by the woman), given chronological age. The remaining exclusionary criteria (hormonal conditions, oophorectomy, fertility medications), rendering 14 women with losses and six women with births ineligible, limit generalizations to women with neither hormonal disorders nor the constellation of circumstances (not all medical) leading to prescription of fertility agents.
A study of particular relevance (van Montfrans et al., 1999 (van Montfrans et al., , 2002 compared women with Down's syndrome births (n = 118) to controls with at least two children and no history of trisomy (n = 102). Mean FSH was calculated from measurements taken in three cycles; the proportion with elevated FSH (the upper 5th percentile in controls) was identi®ed by the highest of the three levels observed. As in our study, inhibin B and estradiol were unrelated to trisomy. In contrast, mean FSH levels were signi®cantly higher in cases: we estimate that their geometric mean was~9% higher in cases than in controls, whereas we observed a downward shift of~5.5%. Strictly speaking, the results of the two studies do not differ (P = 0.10).
In the Down's syndrome study, the odds ratio relating elevated FSH to Down's syndrome births was 3.0 (95% CI 1.1, 8.6). In our study, comparing trisomy spontaneous abortions with live birth controls, the adjusted odds ratio for FSH b10 mIU/ml (the upper 3.1st percentile in controls) was 2.8 (95% CI 0.5, 14.6). Both odds ratios are compatible with the oocyte pool hypothesis. Inferences derived from our sample are insecure, however, because only ®ve cases and two controls had elevated levels. Furthermore, the more powerful test of differences in geometric means suggests that in our sample FSH is not associated with trisomic pregnancy.
Our study, unlike the Down's syndrome study, included trisomies of most autosomes. Accumulating evidence suggests that, although the majority of trisomies derive from error during meiosis I, the predominant mechanism varies with trisomy type (Hassold and Hunt, 2001) . Exploratory analyses of trisomic losses classi®ed in three groupsÐtrisomy 16, other non-acrocentric, acrocentric (including ®ve with trisomy 21)Ð did not suggest older ovarian age in women with acrocentric trisomies.
The exploratory analyses raise the possibility of younger ovarian age in women with trisomy 16 losses than in live birth controls. This result is intriguing because trisomy 16 is unusual: it occurs more often than trisomy of any other chromosome; it increases linearly with maternal age, whereas most other trisomies increase at a faster rate after the midthirties than before (Hassold and Chiu, 1985; Risch et al., 1986) . Two methodological differences require mention. First, the Down's syndrome researchers collected hormone data from three cycles, whereas our data derive from a single cycle. Second, in the Down's syndrome study, residual confounding by chronological age cannot be de®nitively excluded even though the average age of cases and controls was similar.
A potential limitation of our study is that we did not obtain measures from several menstrual cycles. It is uncertain, however, that replicate measures would have improved our estimate of ovarian age. For antral follicle count, one study of women of proven fertility (Scheffer et al., 1999) suggests only modest improvement from replicate measures: the correlations with chronological age of count from a single cycle and from the mean of two cycles were comparable. Moreover, because more than a third of the sample was aged 41±46 years, this study may overestimate intercycle variability in women of reproductive age. For FSH and inhibin B, the literature provides no evidence about intercycle variability in fertile women of reproductive age. For FSH, data from in vitro samples (Scott et al., 1990; Martin et al., 1996) suggest that ovarian age might be better classi®ed by the highest of multiple measures rather than the mean. Given the select sample and special circumstances of IVF and the outcomes (ovarian response and clinical pregnancy), it remains unproven that classi®cation by highest FSH level provides the best indicator of ovarian age.
A countervailing strength of our study is that we measured several different indicators of ovarian age. Three criteriaÐ reliability, validity and biological plausibilityÐsupport the assumption that these measures accurately re¯ect the size of the oocyte pool. The procedure for counting antral follicles was repeatable; the intra-and inter-assay CV for the hormone assays were excellent. The indicators were each associated, in the expected directions, with each other (data not shown) and with chronological age.
The straightforward interpretation of our data is that, contrary to our hypothesis, trisomy risk is unrelated to the size of the oocyte pool. If, indeed, our measures re¯ect the number of developing follicles at the time of the trisomy conception, our data argue against the limited oocyte pool hypothesis (Warburton, 1989) . Neither antral follicle count nor inhibin B was associated with trisomy. Because the hypothesis might apply only when the oocyte pool drops below a critical threshold, we explored whether or not associations changed with chronological age. FSH levels tended to increase more steeply in the late thirties in women with trisomic losses than in women with births. The pattern was not speci®c to trisomic loss, however. Hence, even among older women, our data do not support the hypothesis.
Implications for the biological ageing hypothesis are less clear. Since developing follicles are thought to be the primary source of intraovarian hormones, our data do not support a role for hormonal imbalance associated with depletion of the follicle pool (Brook et al., 1984) . On the other hand, it is possible that the total oocyte pool in¯uences local ovarian or follicular hormone concentrations re¯ected neither by antral follicle count nor by serum hormone levels.
Aside from the Down's syndrome study (van Montfrans et al., 1999) , few epidemiological observations speak directly to the oocyte pool hypothesis. Perhaps the strongest evidence comes from the observation, in our prospective study, that menopause occurred~1 year earlier (95% CI ±2.10, 0.18) among women with trisomic pregnancy losses than among women with chromosomally normal pregnancies (Kline et al., 2000) . We inferred that women with trisomic pregnancies had smaller oocyte pools than other women of the same chronological age, so that they were chronologically younger when their pools dropped below the threshold necessary to maintain menstruation.
In light of our current study, we considered alternative interpretations of the link between trisomic pregnancy and earlier menopause. One possibilityÐthat our ®nding was spuriousÐcan be addressed only by replicate studies. Another possibility is that defects in follicular growth, maturation or composition unrelated to the size of the oocyte pool affect both the likelihood of trisomy and age at menopause. For example, a recent study (Pan et al., 2002) shows that blood¯ow to the ovary decreases monotonically among women who are menstruating, peri-menopausal or post-menopausal.
Research into age-related changes in intraovarian and intrafollicular factors and their relation to non-disjunction is just beginning. Because most data derive from follicles or oocytes exposed to exogenous hormones, interpretation is vulnerable to uncertainty about whether or not exogenous exposure alters the phenomena of interest. Studies which draw on women undergoing IVF have the added complication that ®ndings may not be generalizable to fertile women.
One study (Klein et al., 2000) suggests that age-related differences in serum hormone levels may not be mimicked within the follicle. In the follicular¯uid of dominant follicles, levels of nine hormones (including inhibin B and estradiol) and growth factors were similar for older (40±45 years) and younger (20±25 years) women; four were different. The authors suggest that the increase in the average concentration of vascular endothelial growth factor observed in follicles from older women is linked to meiotic error via diminished oxygen content in the follicular¯uid which, in turn, increases the rate of abnormalities of the meiotic spindle in metaphase II oocytes (Van Blerkom et al., 1997) . The latter observation, derived from follicles aspirated after ovarian stimulation for IVF, has unknown implications for fertile women. An interesting feature of the data, however, was that oxygen concentrations of adjacent follicles often differed, demonstrating inter-follicular differences within women, even holding constant the size of the oocyte pool.
At least one study (Volarcik et al., 1998) implicates factors occurring around the time of oocyte maturation rather than around the time of ovulation. Pre-ovulatory follicles obtained from ovaries unexposed to exogenous hormones were matured in vitro in a hormone-containing culture solution. The rate of misalignment of chromosomes on the spindle (`congression failure') in meiosis II metaphase divisions was higher in oocytes from women aged b35 years than in oocytes from younger women. In addition, the frequency of non-disjunction for four chromosomes at meiosis I was about twice as high in oocytes from older women as in oocytes from younger women. Congression failure was also observed in an earlier study (Battaglia et al., 1996) of fertile women from whom follicles were aspirated, after stimulation with hCG, around the time the dominant follicle reached 15±16 mm, presumably shortly before ovulation. Volarcik et al. (1998) postulated that an age-related defect in folliculogenesis, already present by the late antral stage, increases the risk of meiotic error. Since follicles were cultured in a hormone-containing medium, their result raises the possibility that hormonal conditions at the resumption of meiosis may not affect abnormal chromosome segregation. Other postulated mechanisms include changes in proteins that in¯uence chromosome segregation (Koehler et al., 1996; Watanabe and Nurse 1999; Jeffreys et al., 2003) and the level of oxygenation within the follicle (Van Blerkom et al., 1997) . This is not to say, however, that hormones cannot affect the risk of trisomy. For example, female mice exposed to bisphenol A, a man-made estrogenic compound, have shown increased rates of aneuploidy; experimental studies suggest that even short-term exposure during the ®nal stages of oocyte growth may disrupt meiosis (Hunt et al., 2003) .
Our data indicate that factors in¯uencing meiotic error are unrelated to the number of developing follicles and, most likely, unrelated to the size of the underlying oocyte pool. One implication is that FSH, estradiol and inhibin B, at least as measured in serum, may not affect chromosome segregation. Another implication, of particular relevance in the clinical setting, is that chronological age remains the best predictor of trisomy risk.
